Eli Lilly And Company

This study tested a once-daily oral medication called orforglipron in 1613 adults with obesity or overweight and type 2 diabetes. Participants took either the drug or a placebo for about 77 weeks to see if it helped them lose weight and improve blood sugar control. The goal is to…

This study tested a connected insulin management platform in 36 people with type 1 or type 2 diabetes who use insulin. The goal was to see if the platform helps them remember insulin doses and keep blood sugar in a healthy range. Participants used a continuous glucose monitor and…

This early-stage study tested an experimental drug called LY3437943 in 85 adults with obesity. The goal was to see how the drug affects calorie intake, energy burned, and appetite compared to a placebo. Participants were followed for up to 6 months, and the results will help guid…

This study tested a drug called lebrikizumab in 86 adults and teenagers with moderate-to-severe eczema who had previously used dupilumab. The goal was to see if lebrikizumab could improve skin symptoms like redness, swelling, and itching. Participants received lebrikizumab inject…

This study tested an oral drug called LOXO-305 in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma whose cancer had returned or not responded to prior treatments. The main goal was to see how many patients had their tumors s…

This early-stage study tested whether adding a new drug (LY3841136) to an existing weight-loss medication (tirzepatide) is safe and tolerable. It involved 96 healthy overweight or obese adults and lasted up to 42 weeks. The main goal was to check for side effects, not to measure …

This study tested an experimental oral drug, LY3972406, in 33 adults with moderate-to-severe plaque psoriasis. The main goal was to see if the drug could safely reduce skin symptoms by at least 75% compared to a placebo. Results help determine if further testing is warranted for …

This study tested the safety and effectiveness of the drug abemaciclib combined with other chemotherapy drugs in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to treatment. The goal was to find the best dose and see if the combin…

This study tested whether baricitinib, a pill taken daily, can safely help regrow hair in adults with severe or very severe alopecia areata—a condition causing large bald patches. Over 600 participants received either baricitinib or a placebo for 36 weeks. The main goal was to se…

This study tested the drug baricitinib in 784 adults with severe or very severe alopecia areata, a condition causing major hair loss. Participants received either a low or high dose of baricitinib or a placebo to see if it could regrow scalp hair. The treatment aims to control th…

This study looked at the long-term safety and effectiveness of lebrikizumab for people with moderate-to-severe atopic dermatitis (eczema). Over 1,100 participants who had already been in earlier lebrikizumab studies were followed for up to 33 months. The main goal was to see how …

This early-phase study tested a new drug called LY3039478 in 247 adults with advanced or metastatic cancer (including lymphoma) that had not responded to standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors. Researchers also looked …

This study checked how safe Lyumjev (a rapid-acting insulin) is for adults with type 2 diabetes in India. About 150 people took part and used the insulin for 26 weeks. The main goal was to see how many had low blood sugar episodes. The study is already finished.

This study tested whether a weekly injection of tirzepatide helps people with obesity or overweight maintain weight loss they already achieved. About 441 adults who had lost weight during a 60-week period received either the drug or a placebo. The goal was to see if the drug coul…

This early-phase study tested the safety of combining two drugs, abemaciclib and darolutamide, in 10 men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal was to see if the combination is safe enough to study further. Participan…

This study looked at the safety and side effects of a new drug called LY3841136, given alone or with another drug (tirzepatide), in 128 Japanese adults who are obese or overweight. Participants received multiple doses over several weeks, and researchers monitored for serious side…

This study tested a new drug called orforglipron to see how it affects body fat in 120 adults with obesity or overweight who do not have diabetes. Participants took either the drug or a placebo for about 8 months. The main goal was to measure changes in belly fat and overall body…

This study tested a drug called mirikizumab in people with moderate to severe ulcerative colitis who had already responded to initial treatment. The goal was to see if the drug could keep the disease under control over 40 weeks. About 1,177 adults took part, and the main measure …

This study tested a drug called donanemab (LY3002813) in 272 people with early-stage Alzheimer's disease. The goal was to see if it is safe and can slow down memory and thinking problems. Participants received either the drug or a placebo, and their cognitive abilities were measu…

This study tested two weight-loss medications, tirzepatide and semaglutide, in 751 adults with obesity or overweight who also had related health problems like high blood pressure. Participants did not have diabetes. The trial lasted about 74 weeks and measured how much weight peo…

This study looked at how a single dose of the experimental drug LY3209590 enters and leaves the blood in children with type 2 diabetes. Fifteen children took part, and the study lasted about 100 days. The goal was to understand the drug's processing in the body, not to treat the …

This study tested a new once-daily pill, orforglipron, against an existing pill (oral semaglutide) in 1698 adults with type 2 diabetes whose blood sugar was not well controlled by metformin alone. The goal was to see which pill works better at lowering blood sugar and body weight…

This study tested the drug tirzepatide in children and teenagers aged 10 to 17 with type 2 diabetes that was not well controlled by metformin or insulin. The goal was to see if tirzepatide could lower blood sugar levels better than a placebo. Participants took the drug or a place…

This early-stage study tested an experimental oral drug called LY3549492 in 92 Japanese adults, some with type 2 diabetes and some healthy. The main goal was to check for side effects and see how the drug moves through the body. Researchers gave multiple doses and monitored parti…

This early-stage study tested the safety and tolerability of a new drug called eloralintide, given alone or with another weight-loss drug (tirzepatide), in 188 adults with overweight or obesity. Participants received weekly injections under the skin for up to 26 weeks. Researcher…

This early-stage study tested a single dose of the experimental drug eloralintide in 30 Chinese adults who are overweight or have obesity. The main goal was to check safety and side effects, and to see how the drug moves through the body. Participants received either the drug or …

This study tested a once-weekly medicine called retatrutide in 445 people who are overweight or have obesity and also have knee osteoarthritis. The goal was to see if it helps with weight loss and reduces knee pain. The study lasted about 77 weeks and compared the drug to a place…

This study tested whether two different autoinjectors deliver the same amount of mirikizumab into the bloodstream. 498 healthy adults received a single injection under the skin. The goal was to see if the new 2-mL autoinjector works as well as the standard 1-mL version.

This early-stage study tested the safety and side effects of a new drug called LY3985863 in 24 healthy Chinese adults. Participants received multiple doses under the skin, and researchers monitored how the drug moved through the body. Since this was a Phase 1 trial in healthy peo…

This early-stage study aims to compare how two different pill versions of an experimental drug called LY4064809 are absorbed and processed by the body. It involves 24 healthy adult participants who will stay in a research center for about one month. The main goal is to measure ho…

This early-phase study aimed to understand how kidney function affects how the body processes the cancer drug LOXO-292 (selpercatinib). Researchers compared 37 participants—some with healthy kidneys and some with varying degrees of kidney impairment—after giving them a single dos…

This study tested two different ways to give the experimental drug remternetug to 72 healthy volunteers: an autoinjector (like an EpiPen) and a traditional prefilled syringe. The goal was to see how much drug gets into the bloodstream and how fast the body clears it. Participants…

This study tested the safety and tolerability of a new drug called LY4060874 in 121 healthy people. Participants were monitored for side effects and how the drug moves through the body. The study is complete and does not aim to treat any disease.

This study looked at how a cancer drug called selpercatinib changes the way the body handles repaglinide, a diabetes medication. Sixteen healthy adults took both drugs, and researchers measured how fast repaglinide entered the blood and how quickly it was removed. The goal was to…

This early-stage study tested a new drug called LY3522348 in 65 healthy adults to see if it is safe and what side effects it might cause. Researchers also measured how much of the drug gets into the blood and how fast the body gets rid of it. The study had two parts, lasting up t…

This study looked at how two different capsule forms of the drug olomorasib are absorbed in the body and whether food changes that absorption. It involved 191 healthy Japanese adults and lasted about 6 weeks. The goal was to gather information, not to treat any disease.

This study looked at how a high-fat meal and a common stomach-acid drug (omeprazole) affect the way selpercatinib enters and leaves the body. Twenty healthy adults took part, and researchers measured drug levels in the blood under different conditions. The goal was to gather safe…

This early-stage study tested a new drug called LY3451838 in 53 healthy adults to check its safety and how the body handles it. Participants received a single dose either into a vein or just under the skin. The main goal was to track any side effects and measure drug levels in th…

This study looked at how imlunestrant enters the blood and leaves the body in women with and without liver problems. 27 women took part to help researchers understand the drug's behavior. The goal was not to treat a disease but to gather important safety and dosing information.

This study looked at how a cancer drug called selpercatinib changes the way the body processes midazolam, a sedative. Sixteen healthy adults took both drugs, and researchers measured drug levels in the blood. The goal was to see if selpercatinib affects how fast midazolam is abso…

This study looked at how a single dose of selpercatinib changes the amount of rosuvastatin in the blood of 28 healthy adults. Participants took both drugs and had their blood levels measured. The goal was to understand the drug interaction, not to treat any disease. Results help …

This study looked at how different versions of the drug bimagrumab, given alone or together with tirzepatide, are absorbed by the body. It involved 125 healthy adults and lasted about 4.5 months. The goal was to measure drug levels, not to treat any disease.

This early-stage study tested the safety and side effects of a single dose of lebrikizumab compared to a placebo in 24 healthy Chinese adults. Researchers also measured how fast the drug enters the blood and how long it stays in the body. The study did not aim to treat any diseas…

This study tested a new drug called LY3484356 in 87 postmenopausal women with early-stage (stage I-III) estrogen receptor-positive, HER2-negative breast cancer. The drug was given for a short time before surgery to see if it was safe and how it affected the cancer cells. The main…

This study looked at how a drug called LY3484356 enters the bloodstream and leaves the body. Sixteen healthy women who cannot become pregnant took a single dose with a tiny radioactive tag. Researchers measured the drug and its breakdown products in blood, urine, stool, and breat…

This early-stage study tested whether the experimental drug LY3985297 is safe and tolerable in 140 healthy adults. Participants received either a single dose or multiple doses through an IV or injection under the skin. The study measured side effects and how the drug moves throug…

This study looked at how much of the drug LY4064809 gets into the blood and how fast the body gets rid of it. Ten healthy Chinese adults took the drug by mouth and were monitored for about 21 days. The goal was to learn about the drug's safety and how the body processes it, not t…

This study looked at how taking imlunestrant multiple times affects the way the body handles another drug called midazolam. It involved 20 healthy women who were not able to become pregnant. The goal was to measure drug levels in the blood and check for safety, helping researcher…

This early-stage study tested a new drug called LY3526318 in 16 healthy adults. The goal was to see how the body absorbs and gets rid of the drug, and to check for any side effects. Participants took the drug by mouth either once or multiple times, and the study lasted up to 50 d…

This study looked at how food and certain other drugs (omeprazole, itraconazole, carbamazepine) affect the levels of a new medicine called LY3484356 in the blood. It involved 82 healthy women who cannot become pregnant. The goal was to understand how the body processes the drug, …

This study looked at how two common drugs, itraconazole and rifampin, change the way the body processes selpercatinib, a cancer treatment. Twenty-four healthy adults took selpercatinib alone and then with each of the other drugs. Researchers measured drug levels in the blood to u…

This study looked at how a single dose of the cancer drug Selpercatinib (LOXO-292) affects the heart's electrical activity in 32 healthy adults. Participants took the drug, a placebo, or a positive control in random order, and had their heart rhythm measured by ECG. The goal was …

This study tested a new drug called LY4268989 in 144 healthy adults, including Japanese and Chinese participants. The goal was to see how the body absorbs and processes the drug, how safe it is, and whether food or other medications affect it. No treatment benefit was expected; t…

This early-stage study looked at how a single dose of the drug LY3526318 affects blood flow in the skin of healthy women. Researchers used special imaging to measure changes after applying a cinnamon-like substance. The study involved 16 participants and was completed by Eli Lill…